Skip to main content
Top
Published in: BMC Medical Research Methodology 1/2018

Open Access 01-12-2018 | Research article

Methods for evaluating adverse drug event preventability in emergency department patients

Authors: Stephanie A. Woo, Amber Cragg, Maeve E. Wickham, David Peddie, Ellen Balka, Frank Scheuermeyer, Diane Villanyi, Corinne M. Hohl

Published in: BMC Medical Research Methodology | Issue 1/2018

Login to get access

Abstract

Background

There is a high degree of variability in assessing the preventability of adverse drug events, limiting the ability to compare rates of preventable adverse drug events across different studies. We compared three methods for determining preventability of adverse drug events in emergency department patients and explored their strengths and weaknesses.

Methods

This mixed-methods study enrolled emergency department patients diagnosed with at least one adverse drug event from three prior prospective studies. A clinical pharmacist and physician reviewed the medical and research records of all patients, and independently rated each event’s preventability using a “best practice-based” approach, an “error-based” approach, and an “algorithm-based” approach. Raters discussed discordant ratings until reaching consensus. We assessed the inter-rater agreement between clinicians using the same assessment method, and between different assessment methods using Cohen’s kappa with 95% confidence intervals (95% CI). Qualitative researchers observed discussions, took field notes, and reviewed free text comments made by clinicians in a “comment” box in the data collection form. We developed a coding structure and iteratively analyzed qualitative data for emerging themes regarding the application of each preventability assessment method using NVivo.

Results

Among 1356 adverse drug events, a best practice-based approach rated 64.1% (95% CI: 61.5–66.6%) of events as preventable, an error-based approach rated 64.3% (95% CI: 61.8–66.9%) of events as preventable, and an algorithm-based approach rated 68.8% (95% CI: 66.1–71.1%) of events as preventable. When applying the same method, the inter-rater agreement between clinicians was 0.53 (95% CI: 0.48–0.59), 0.55 (95%CI: 0.50–0.60) and 0.55 (95% CI: 0.49–0.55) for the best practice-, error-, and algorithm-based approaches, respectively. The inter-rater agreement between different assessment methods using consensus ratings for each ranged between 0.88 (95% CI 0.85–0.91) and 0.99 (95% CI 0.98–1.00). Compared to a best practice-based assessment, clinicians believed the algorithm-based assessment was too rigid. It did not account for the complexities of and variations in clinical practice, and frequently was too definitive when assigning preventability ratings.

Conclusion

There was good agreement between all three methods of determining the preventability of adverse drug events. However, clinicians found the algorithmic approach constraining, and preferred a best practice-based assessment method.
Appendix
Available only for authorised users
Literature
1.
go back to reference Budnitz DS, Lovegrove MC, Shehab N, Richards CL. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med. 2011;365:2002–12.CrossRefPubMed Budnitz DS, Lovegrove MC, Shehab N, Richards CL. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med. 2011;365:2002–12.CrossRefPubMed
2.
go back to reference Hohl CM, Badke K, Zhao A, et al. Prospective validation of clinical criteria to identify emergency department patients at high risk for adverse drug events. Acad Emerg Med. 2018;25(9):1015–1026.CrossRefPubMedPubMedCentral Hohl CM, Badke K, Zhao A, et al. Prospective validation of clinical criteria to identify emergency department patients at high risk for adverse drug events. Acad Emerg Med. 2018;25(9):1015–1026.CrossRefPubMedPubMedCentral
3.
go back to reference Hohl CM, Yu E, Hunte GS, et al. Clinical decision rules to improve the detection of adverse drug events in emergency department patients. Acad Emerg Med. 2012;19:640–9.CrossRefPubMed Hohl CM, Yu E, Hunte GS, et al. Clinical decision rules to improve the detection of adverse drug events in emergency department patients. Acad Emerg Med. 2012;19:640–9.CrossRefPubMed
4.
go back to reference Zed PJ, Abu-Laban RB, Balen RM, et al. Incidence, severity and preventability of medication-related visits to the emergency department: a prospective study. CMAJ. 2008;178:1563–9.CrossRefPubMedPubMedCentral Zed PJ, Abu-Laban RB, Balen RM, et al. Incidence, severity and preventability of medication-related visits to the emergency department: a prospective study. CMAJ. 2008;178:1563–9.CrossRefPubMedPubMedCentral
5.
go back to reference Hohl CM, Partovi N, Ghement I, et al. Impact of early in-hospital medication review by clinical pharmacists on health services utilization. PLoS One. 2017;12.CrossRefPubMedPubMedCentral Hohl CM, Partovi N, Ghement I, et al. Impact of early in-hospital medication review by clinical pharmacists on health services utilization. PLoS One. 2017;12.CrossRefPubMedPubMedCentral
6.
go back to reference The WHO Research Priority Setting Working Group. Global Priorities for Research in Patient Safety (first edition): World Health Organization; 2008. The WHO Research Priority Setting Working Group. Global Priorities for Research in Patient Safety (first edition): World Health Organization; 2008.
7.
go back to reference Hohl CM, Dankoff J, Colacone A, Afilalo M. Polypharmacy, adverse drug-related events, and potential adverse drug interactions in elderly patients presenting to an emergency department. Ann Emerg Med. 2001;38:666–71.CrossRef Hohl CM, Dankoff J, Colacone A, Afilalo M. Polypharmacy, adverse drug-related events, and potential adverse drug interactions in elderly patients presenting to an emergency department. Ann Emerg Med. 2001;38:666–71.CrossRef
8.
go back to reference Hohl CM, Nosyk B, Kuramoto L, et al. Outcomes of emergency department patients presenting with adverse drug events. Ann Emerg Med. 2011;58:270–9.CrossRefPubMed Hohl CM, Nosyk B, Kuramoto L, et al. Outcomes of emergency department patients presenting with adverse drug events. Ann Emerg Med. 2011;58:270–9.CrossRefPubMed
9.
go back to reference Krahenbuhl-Melcher A, Schlienger R, Lampert M, Haschke M, Drewe J, Krahenbuhl S. Drug-related problems in hospitals: a review of the recent literature. Drug Saf. 2007;30:379–407.CrossRef Krahenbuhl-Melcher A, Schlienger R, Lampert M, Haschke M, Drewe J, Krahenbuhl S. Drug-related problems in hospitals: a review of the recent literature. Drug Saf. 2007;30:379–407.CrossRef
10.
go back to reference Thomsen LA, Winterstein AG, Sondergaard B, Haugbolle LS, Melander A. Systematic review of the incidence and characteristics of preventable adverse drug events in ambulatory care. Ann Pharmacother. 2007;41:1411–26.CrossRefPubMed Thomsen LA, Winterstein AG, Sondergaard B, Haugbolle LS, Melander A. Systematic review of the incidence and characteristics of preventable adverse drug events in ambulatory care. Ann Pharmacother. 2007;41:1411–26.CrossRefPubMed
11.
go back to reference WHO Research Priority Setting Working Group. Global priorities for research in patient safety (first edition): World Health Organization; 2008. WHO Research Priority Setting Working Group. Global priorities for research in patient safety (first edition): World Health Organization; 2008.
12.
go back to reference Bates DW, Cullen DJ, Laird N, et al. Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE prevention study group. Jama. 1995;274:29–34.CrossRefPubMed Bates DW, Cullen DJ, Laird N, et al. Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE prevention study group. Jama. 1995;274:29–34.CrossRefPubMed
13.
go back to reference Bates DW, Leape LL, Petrycki S. Incidence and preventability of adverse drug events in hospitalized adults. J Gen Intern Med. 1993;8:289–94.CrossRefPubMed Bates DW, Leape LL, Petrycki S. Incidence and preventability of adverse drug events in hospitalized adults. J Gen Intern Med. 1993;8:289–94.CrossRefPubMed
14.
go back to reference Classen DC, Pestotnik SL, Evans RS, Burke JP. Computerized surveillance of adverse drug events in hospital patients. Jama. 1991;266:2847–51.CrossRefPubMed Classen DC, Pestotnik SL, Evans RS, Burke JP. Computerized surveillance of adverse drug events in hospital patients. Jama. 1991;266:2847–51.CrossRefPubMed
15.
go back to reference Franceschi M, Scarcelli C, Niro V, et al. Prevalence, clinical features and avoidability of adverse drug reactions as cause of admission to a geriatric unit: a prospective study of 1756 patients. Drug Saf. 2008;31:545–56.CrossRefPubMed Franceschi M, Scarcelli C, Niro V, et al. Prevalence, clinical features and avoidability of adverse drug reactions as cause of admission to a geriatric unit: a prospective study of 1756 patients. Drug Saf. 2008;31:545–56.CrossRefPubMed
16.
go back to reference Gholami K, Shalviri G. Factors associated with preventability, predictability, and severity of adverse drug reactions. Ann Pharmacother. 1999;33:236–40.CrossRefPubMed Gholami K, Shalviri G. Factors associated with preventability, predictability, and severity of adverse drug reactions. Ann Pharmacother. 1999;33:236–40.CrossRefPubMed
17.
go back to reference Gurwitz JH, Field TS, Avorn J, et al. Incidence and preventability of adverse drug events in nursing homes. Am J Med. 2000;109:87–94.CrossRefPubMed Gurwitz JH, Field TS, Avorn J, et al. Incidence and preventability of adverse drug events in nursing homes. Am J Med. 2000;109:87–94.CrossRefPubMed
18.
go back to reference Lagnaoui R, Moore N, Fach J, Longy-Boursier M, Begaud B. Adverse drug reactions in a department of systemic diseases-oriented internal medicine: prevalence, incidence, direct costs and avoidability. Eur J Clin Pharmacol. 2000;56:181–6.CrossRefPubMed Lagnaoui R, Moore N, Fach J, Longy-Boursier M, Begaud B. Adverse drug reactions in a department of systemic diseases-oriented internal medicine: prevalence, incidence, direct costs and avoidability. Eur J Clin Pharmacol. 2000;56:181–6.CrossRefPubMed
19.
go back to reference Tafreshi MJ, Melby MJ, Kaback KR, Nord TC. Medication-related visits to the emergency department: a prospective study. Ann Pharmacother. 1999;33:1252–7.CrossRefPubMed Tafreshi MJ, Melby MJ, Kaback KR, Nord TC. Medication-related visits to the emergency department: a prospective study. Ann Pharmacother. 1999;33:1252–7.CrossRefPubMed
20.
go back to reference Ferner RE, Aronson JK. Preventability of drug-related harms - part I: a systematic review. Drug Saf. 2010;33:985–94.CrossRefPubMed Ferner RE, Aronson JK. Preventability of drug-related harms - part I: a systematic review. Drug Saf. 2010;33:985–94.CrossRefPubMed
21.
go back to reference Hakkarainen KM, Andersson Sundell K, Petzold M, Hagg S. Methods for assessing the preventability of adverse drug events: a systematic review. Drug Saf. 2012;35:105–26.CrossRefPubMed Hakkarainen KM, Andersson Sundell K, Petzold M, Hagg S. Methods for assessing the preventability of adverse drug events: a systematic review. Drug Saf. 2012;35:105–26.CrossRefPubMed
22.
go back to reference Hallas J, Harvald B, Gram LF, et al. Drug related hospital admissions: the role of definitions and intensity of data collection, and the possibility of prevention. J Intern Med. 1990;228:83–90.CrossRefPubMed Hallas J, Harvald B, Gram LF, et al. Drug related hospital admissions: the role of definitions and intensity of data collection, and the possibility of prevention. J Intern Med. 1990;228:83–90.CrossRefPubMed
23.
go back to reference Health Canada. Adverse reaction information. 2012. Health Canada. Adverse reaction information. 2012.
24.
go back to reference Schumock GT, Thornton JP. Focusing on the preventability of adverse drug reactions. Hosp Pharm. 1992;27:538.PubMed Schumock GT, Thornton JP. Focusing on the preventability of adverse drug reactions. Hosp Pharm. 1992;27:538.PubMed
25.
go back to reference Hohl CM, McGrail K, Sobolev B. The effect of pharmacist-led medication review in high-risk patients in the emergency department: an evaluation protocol. CMAJ Open. 2015;3:E103–10.CrossRefPubMedPubMedCentral Hohl CM, McGrail K, Sobolev B. The effect of pharmacist-led medication review in high-risk patients in the emergency department: an evaluation protocol. CMAJ Open. 2015;3:E103–10.CrossRefPubMedPubMedCentral
26.
go back to reference Nebeker J, Barach P, Samore M. Clarifying adverse drug events: a clinician’s guide to terminology, documentation, and reporting. Ann Intern Med. 2004;140:795–801.CrossRefPubMed Nebeker J, Barach P, Samore M. Clarifying adverse drug events: a clinician’s guide to terminology, documentation, and reporting. Ann Intern Med. 2004;140:795–801.CrossRefPubMed
27.
go back to reference World Health Organization. International drug monitoring: the role of the hospital, report of a WHO meeting. Geneva: World Health Organization; 1969. World Health Organization. International drug monitoring: the role of the hospital, report of a WHO meeting. Geneva: World Health Organization; 1969.
28.
go back to reference Verelst S, Jacques J, Van den Heede K, et al. Validation of hospital administrative dataset for adverse event screening. Qual Saf Health Care. 2010;19:e25.PubMed Verelst S, Jacques J, Van den Heede K, et al. Validation of hospital administrative dataset for adverse event screening. Qual Saf Health Care. 2010;19:e25.PubMed
29.
go back to reference Raut LA, Patel P, Patel C, Pawar A. Preventability, predictability and seriousness of adverse drug reactions in among medicine inpatients in a teaching hospital: a prospective observational study. IJPCS. 2012;1:1293–9. Raut LA, Patel P, Patel C, Pawar A. Preventability, predictability and seriousness of adverse drug reactions in among medicine inpatients in a teaching hospital: a prospective observational study. IJPCS. 2012;1:1293–9.
30.
go back to reference Ducharme MM, Boothby LA. Analysis of adverse drug reactions for preventability. Int J Clin Pract. 2007;61:157–61.CrossRefPubMed Ducharme MM, Boothby LA. Analysis of adverse drug reactions for preventability. Int J Clin Pract. 2007;61:157–61.CrossRefPubMed
31.
go back to reference Leape LL, Brennan TA, Laird N, et al. The nature of adverse events in hospitalized patients. Results of the Harvard medical practice study II. N Engl J Med. 1991;324:377–84.CrossRef Leape LL, Brennan TA, Laird N, et al. The nature of adverse events in hospitalized patients. Results of the Harvard medical practice study II. N Engl J Med. 1991;324:377–84.CrossRef
32.
go back to reference van der Linden CM, Jansen PA, Grouls RJ, et al. Systems that prevent unwanted represcription of drugs withdrawn because of adverse drug events: a systematic review. Ther Adv Drug Saf. 2013;4:73–90.CrossRefPubMedPubMedCentral van der Linden CM, Jansen PA, Grouls RJ, et al. Systems that prevent unwanted represcription of drugs withdrawn because of adverse drug events: a systematic review. Ther Adv Drug Saf. 2013;4:73–90.CrossRefPubMedPubMedCentral
33.
go back to reference van der Linden CM, Jansen PA, van Marum RJ, Grouls RJ, Korsten EH, Egberts AC. Recurrence of adverse drug reactions following inappropriate re-prescription: better documentation, availability of information and monitoring are needed. Drug Saf. 2010;33:535–8.CrossRefPubMed van der Linden CM, Jansen PA, van Marum RJ, Grouls RJ, Korsten EH, Egberts AC. Recurrence of adverse drug reactions following inappropriate re-prescription: better documentation, availability of information and monitoring are needed. Drug Saf. 2010;33:535–8.CrossRefPubMed
35.
go back to reference Hayward RA, McMahon LF Jr, Bernard AM. Evaluating the care of general medicine inpatients: how good is implicit review? Ann Intern Med. 1993;118:550–6.CrossRefPubMed Hayward RA, McMahon LF Jr, Bernard AM. Evaluating the care of general medicine inpatients: how good is implicit review? Ann Intern Med. 1993;118:550–6.CrossRefPubMed
36.
go back to reference Kerr EA, Smith DM, Hogan MM, et al. Building a better quality measure: are some patients with 'poor quality' actually getting good care? Med Care. 2003;41:1173–82.CrossRefPubMed Kerr EA, Smith DM, Hogan MM, et al. Building a better quality measure: are some patients with 'poor quality' actually getting good care? Med Care. 2003;41:1173–82.CrossRefPubMed
37.
go back to reference Rubenstein LV, Kahn KL, Reinisch EJ, et al. Changes in quality of care for five diseases measured by implicit review, 1981 to 1986. Jama. 1990;264:1974–9.CrossRefPubMed Rubenstein LV, Kahn KL, Reinisch EJ, et al. Changes in quality of care for five diseases measured by implicit review, 1981 to 1986. Jama. 1990;264:1974–9.CrossRefPubMed
38.
go back to reference Werth L, Strack F, Förster J. Certainty and uncertainty: the two faces of the hindsight Bias. Organ Behav Hum Decis Process. 2002;87:323–41.CrossRef Werth L, Strack F, Förster J. Certainty and uncertainty: the two faces of the hindsight Bias. Organ Behav Hum Decis Process. 2002;87:323–41.CrossRef
40.
go back to reference Reason J. The contribution of latent human failures to the breakdown of complex systems. Philos Trans R Soc Lond Ser B Biol Sci. 1990;327:475–84.CrossRef Reason J. The contribution of latent human failures to the breakdown of complex systems. Philos Trans R Soc Lond Ser B Biol Sci. 1990;327:475–84.CrossRef
41.
go back to reference Owen RR, Thrush CR, Hudson TJ, et al. Using an explicit guideline-based criterion and implicit review to assess antipsychotic dosing performance for schizophrenia. Int J Qual Health Care. 2002;14:199–206.CrossRefPubMed Owen RR, Thrush CR, Hudson TJ, et al. Using an explicit guideline-based criterion and implicit review to assess antipsychotic dosing performance for schizophrenia. Int J Qual Health Care. 2002;14:199–206.CrossRefPubMed
42.
go back to reference Wheeler A. Explicit versus implicit review to explore combination antipsychotic prescribing. J Eval Clin Pract. 2009;15:685–91.CrossRefPubMed Wheeler A. Explicit versus implicit review to explore combination antipsychotic prescribing. J Eval Clin Pract. 2009;15:685–91.CrossRefPubMed
43.
go back to reference Duckett S. What problem is being solved: 'Preventability' and the case of pricing for safety and quality. Asia Pacific J Health Manag. 2016;11:18–21. Duckett S. What problem is being solved: 'Preventability' and the case of pricing for safety and quality. Asia Pacific J Health Manag. 2016;11:18–21.
44.
go back to reference Smith MA, Atherly AJ, Kane RL, Pacala JT. Peer review of the quality of care. Reliability and sources of variability for outcome and process assessments. Jama. 1997;278:1573–8.CrossRefPubMed Smith MA, Atherly AJ, Kane RL, Pacala JT. Peer review of the quality of care. Reliability and sources of variability for outcome and process assessments. Jama. 1997;278:1573–8.CrossRefPubMed
45.
go back to reference Weingart SN, Davis RB, Palmer RH, et al. Discrepancies between explicit and implicit review: physician and nurse assessments of complications and quality. Health Serv Res. 2002;37:483–98.CrossRefPubMedPubMedCentral Weingart SN, Davis RB, Palmer RH, et al. Discrepancies between explicit and implicit review: physician and nurse assessments of complications and quality. Health Serv Res. 2002;37:483–98.CrossRefPubMedPubMedCentral
Metadata
Title
Methods for evaluating adverse drug event preventability in emergency department patients
Authors
Stephanie A. Woo
Amber Cragg
Maeve E. Wickham
David Peddie
Ellen Balka
Frank Scheuermeyer
Diane Villanyi
Corinne M. Hohl
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Medical Research Methodology / Issue 1/2018
Electronic ISSN: 1471-2288
DOI
https://doi.org/10.1186/s12874-018-0617-4

Other articles of this Issue 1/2018

BMC Medical Research Methodology 1/2018 Go to the issue